Cardiovascular Disorders Drug Development Pipeline Review, 2017

US$ 3995

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels.

04-04 2017   Pages: 432

Antibacterial Therapies Drug Development Pipeline Review, 2017

US$ 3995

Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the body’s immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future.

04-04 2017   Pages: 418

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

US$ 4995

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases.

04-04 2017   Pages: 161

Frontier Pharma: Head and Neck Cancer – Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

US$ 6995

Head and neck squamous cell carcinoma is the sixth most common cancer, and its incidence is rising. The term head and neck cancer (HNC) comprises a number of malignancies that usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck.

04-04 2017   Pages: 78

Global Respiratory Complications Therapeutics Market to 2022 – Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

US$ 4995

The respiratory therapy area consists of indications that affect the respiratory system in various ways, including the scarring of lung tissue and excessive production of mucus in the airways, thereby decreasing lung function.

04-04 2017   Pages: 197

Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies

US$ 4995

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult.

02-03 2017   Pages: 108

Frontier Pharma: Melanoma Therapeutics – Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

US$ 6995

Melanoma is a type of cancer that begins in the melanocytes, often in moles or other pigmented tissues. It most commonly affects the skin, as cutaneous melanoma; however it can also affect other pigmented tissues, such as the eye or intestines, as extracutaneous melanoma. It is the deadliest form of skin cancer and remains one of the most aggressive and treatment-resistant human cancers.

02-03 2017   Pages: 81

United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022

US$ 1000

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.

12-19 2016   Pages: 122

Diabetes & Obesity Drug Development Pipeline Review, 2016

US$ 3995

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.

11-22 2016   Pages: 560

Ophthalmology Drug Development Pipeline Review, 2016

US$ 3995

Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, and particularly blindness, can arise.

11-22 2016   Pages: 633
Contact With Us
Join templatemonster at google+
Customized Research
Request Sample